Van ECK Associates Corp Purchases 23,733 Shares of BioNTech SE (NASDAQ:BNTX)

Van ECK Associates Corp boosted its holdings in BioNTech SE (NASDAQ:BNTX - Free Report) by 25.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 118,418 shares of the company's stock after purchasing an additional 23,733 shares during the period. Van ECK Associates Corp's holdings in BioNTech were worth $13,493,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in BNTX. FMR LLC lifted its stake in BioNTech by 797.8% in the third quarter. FMR LLC now owns 6,299,929 shares of the company's stock worth $748,243,000 after purchasing an additional 5,598,190 shares during the last quarter. Fred Alger Management LLC bought a new position in shares of BioNTech during the third quarter valued at about $59,485,000. Braidwell LP bought a new position in shares of BioNTech during the third quarter valued at about $29,425,000. New York State Common Retirement Fund raised its stake in shares of BioNTech by 457.9% during the third quarter. New York State Common Retirement Fund now owns 218,067 shares of the company's stock valued at $25,900,000 after acquiring an additional 178,981 shares during the last quarter. Finally, abrdn plc raised its stake in shares of BioNTech by 334.4% during the third quarter. abrdn plc now owns 225,992 shares of the company's stock valued at $26,841,000 after acquiring an additional 173,969 shares during the last quarter. 15.52% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on BNTX. Berenberg Bank began coverage on shares of BioNTech in a research note on Tuesday, November 19th. They set a "buy" rating and a $130.00 price objective for the company. TD Cowen lowered their price objective on shares of BioNTech from $132.00 to $122.00 and set a "hold" rating for the company in a research note on Tuesday, November 5th. The Goldman Sachs Group raised shares of BioNTech from a "neutral" rating to a "buy" rating and upped their price objective for the company from $90.00 to $137.00 in a research note on Friday, November 8th. Evercore ISI upgraded shares of BioNTech from an "in-line" rating to an "outperform" rating and boosted their price target for the company from $110.00 to $125.00 in a research report on Tuesday, November 19th. Finally, JPMorgan Chase & Co. reduced their price target on shares of BioNTech from $124.00 to $122.00 and set a "neutral" rating on the stock in a research report on Tuesday, November 26th. Three research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $142.72.

BioNTech Stock Up 2.4 %

Shares of NASDAQ BNTX traded up $2.92 during trading on Tuesday, reaching $122.75. The company had a trading volume of 709,998 shares, compared to its average volume of 729,390. BioNTech SE has a 12-month low of $76.53 and a 12-month high of $131.49. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The business's 50-day moving average is $117.32 and its 200 day moving average is $110.18. The stock has a market cap of $29.43 billion, a PE ratio of -58.45 and a beta of 0.17.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.